^
Association details:
Biomarker:No biomarker
Cancer:Marginal Zone Lymphoma
Drug:Zydelig (idelalisib) (PI3Kδ inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Marginal Zone Lymphoma: Second-line and Subsequent Therapy...Other recommended regimens…PI3K inhibitors (relapsed/refractory after 2 prior therapies)…Idelalisib